CDC panel backs full licensing of Pfizer-BioNTech COVID-19 vaccine
The Pfizer-BioNTech COVID-19 vaccine remains extremely safe and worth using a federal advisory committee agreed Monday, recommending its use in people over 16.
The committee, known as the Advisory Committee on Immunization Practices (ACIP), reviewed data presented as part of the companies' request for a full license for the vaccine.
The vaccine had been authorized for emergency use; on Aug. 23, the Food and Drug Administration issued it a biologics license application the technical term for full approval in people 16 and up. Its use in adolescents 12-15 will continue to have emergency authorization until more data accumulates.
Emergency use was granted to speed the vaccine's availability during a time of crisis, based on two months' worth of data. Full approval is based on six months' worth.
https://www.msn.com/en-us/news/us/cdc-panel-backs-full-licensing-of-pfizer-biontech-covid-19-vaccine/ar-AANUHt9